Skip to main content
HCAT
NASDAQ Technology

Health Catalyst Reports Preliminary 2025 Results Exceeding Revenue and Client Targets, Outlines 2026 Strategic Focus

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Positive
Importance info
7
Price
$2.46
Mkt Cap
$173.998M
52W Low
$2.015
52W High
$7.25
Market data snapshot near publication time

summarizeSummary

Health Catalyst, Inc. announced preliminary unaudited 2025 financial results, reporting revenue slightly above guidance and new platform clients exceeding targets, alongside strategic updates for 2026.


check_boxKey Events

  • Preliminary 2025 Financial Performance

    Health Catalyst reported preliminary unaudited 2025 results, with total revenue slightly exceeding guidance of ~$310M and Adjusted EBITDA in line with ~$41M guidance.

  • Strong Client Acquisition

    The company added 32 net new Platform Clients, surpassing its target of 30, with average annual recurring revenue (ARR) and non-recurring revenue near the midpoint of the $300k to $700k range.

  • Strategic Focus for 2026

    Health Catalyst plans to sharpen its strategic focus on core offerings, rebalance investments, and continue advancing its client-centric Ignite migration efforts.

  • Operational and Growth Initiatives

    Plans include increased investment in India resourcing and AI utilization in 2026, with an expectation of higher overall bookings than in 2025.


auto_awesomeAnalysis

This 8-K filing provides investors with an early look at Health Catalyst's 2025 performance, indicating stronger-than-expected revenue and client acquisition. The company's strategic focus on core offerings, client-centric migration, and investment in AI and India resourcing for 2026 suggests a proactive approach to enhancing value and optimizing costs. While these results are preliminary and subject to audit, the positive trends and forward-looking commentary offer a favorable outlook for the company's operational and financial trajectory. Investors should monitor the upcoming full earnings call for more detailed 2026 guidance and audited results.

At the time of this filing, HCAT was trading at $2.46 on NASDAQ in the Technology sector, with a market capitalization of approximately $174M. The 52-week trading range was $2.02 to $7.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HCAT - Latest Insights

HCAT
Apr 27, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
HCAT
Apr 02, 2026, 5:56 PM EDT
Filing Type: 8-K
Importance Score:
7
HCAT
Mar 12, 2026, 4:58 PM EDT
Filing Type: 10-K
Importance Score:
9
HCAT
Mar 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
HCAT
Mar 12, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
HCAT
Feb 18, 2026, 1:04 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
HCAT
Feb 18, 2026, 8:59 AM EST
Filing Type: 8-K
Importance Score:
9
HCAT
Jan 23, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
HCAT
Jan 21, 2026, 8:39 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
HCAT
Jan 12, 2026, 4:26 PM EST
Filing Type: 8-K
Importance Score:
7